title: Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
abstract: Receptor targeted therapy is advantageous in overcoming the toxicity burden of conventional cancer chemotherapeutics. Over expression of epidermal growth factor receptor (EGFR) on cancer cells and its role in metastasis, malignancy and drug resistance in many human cancers lead to its selection as a promising target for cancer treatment. The present work investigated the preparation and characterization of docetaxel (DTXL) loaded gamma-poly (glutamic acid) (gamma-PGA) nanoparticles (Nps) conjugated with EGFR antibody (Cetuximab, CET) targeted to colon cancer cells (HT-29), highly over expressing EGFR. The flow cytometric analysis revealed two fold increased cellular uptake of CET-DTXL-gamma-PGA Nps by HT-29 (EGFR +ve) cells compared to that of IEC-6 (EGFR-ve) cells confirming the active targeting. Cytotoxicity assays (MTT and LDH) showed superior anti-proliferative activity of CET-DTXL-gamma-PGA NPs over DTXL-gamma-PGA Nps against HT-29 cells. The cell cycle analysis indicated that CET-DTXL-gamma-PGA NPs induced cell death in enhanced percentage of HT-29 cells by undergoing cell cycle arrest in G2/M phase compared to that of DTXL-gamma-PGA Nps. The mechanism of cancer cell death was analyzed via apoptotic and mitochondrial membrane potential assays and showed that targeted Nps treatment reduced the mitochondrial membrane potential thereby inducing enhanced HT-29 cell death (apoptosis and necrosis). The biodistribution of targeted and non-targeted Nps were analyzed in vivo in Swiss albino mice using NIR imaging. ICG-CET-DTXL-gamma-PGA Nps (targeted) and ICG-DTXL-gamma-PGA Nps (non-targeted) followed the similar biodistribution pattern in vivo, but with different elimination time. In short, CET-DTXL-gamma-PGA nanoparticles enhance the tumor selective therapeutic efficacy for colon cancer.
authors.forename: S
authors.initials: S
authors.lastname: Maya
authors.forename: Bruno
authors.initials: B
authors.lastname: Sarmento
authors.forename: Vinoth-Kumar
authors.initials: VK
authors.lastname: Lakshmanan
authors.forename: Deepthy
authors.initials: D
authors.lastname: Menon
authors.forename: R
authors.initials: R
authors.lastname: Jayakumar
mesh_terms: D000818:Animals; D017302:Annexins / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D001562:Benzimidazoles; D002232:Carbocyanines; D002453:Cell Cycle / Q000187:drug effects; D016923:Cell Death / Q000187:drug effects; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000378:metabolism*; D000077143:Docetaxel; D004337:Drug Carriers / Q000737:chemistry*; D066246:ErbB Receptors / Q000378:metabolism*; D019073:HT29 Cells; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D051379:Mice; D050997:Nanomedicine; D053758:Nanoparticles / Q000737:chemistry; D011099:Polyglutamic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D043823:Taxoids / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D014018:Tissue Distribution
chemical_list: D017302:Annexins; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D002232:Carbocyanines; D004337:Drug Carriers; D043823:Taxoids; C511775:poly(gamma-glutamic acid); D000077143:Docetaxel; C068624:5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine; D011099:Polyglutamic Acid; D066246:ErbB Receptors; D000068818:Cetuximab